Juq-063 [2021] ✮

JUQ-063 is the production code for a Japanese adult video (JAV) titled "I Can’t Tell My Wife Even If My Mouth Is Torn, I Can’t Believe I Got My Mother-in-Law Pregnant," released in August 2022. The film is produced by the studio Madonna , which specializes in "mature" or "milf" themed content, and stars the popular actress Aoi Ichino . Production Details and Overview The film is a drama-heavy production following a common trope in the JAV genre: the forbidden relationship within a family setting. Starring: Aoi Ichino Studio: Madonna Release Date: August 18, 2022 Duration: Approximately 120 minutes Genres: Mature, Married Woman, Big Tits, Drama, Hot Spring Plot Summary The narrative centers on a family trip to a hot spring (onsen). According to Jav Trailers and MemoJav , the protagonist (the husband) and his wife travel with her mother. The story takes a turn when the wife unexpectedly starts her period, leading to a series of events where the husband ends up in a secret sexual encounter with his mother-in-law, played by Aoi Ichino. The title refers to the central conflict of the story: the husband's inability to confess that he has impregnated his wife's mother during the trip. Availability and Versions As a commercial production, JUQ-063 was released in several formats and versions: Standard Release: The original censored version featuring digital mosaics, typical of mainstream Japanese adult media. Uncensored Leaks: There are reports and listings on sites like Javdock and Sextb for "Uncensored Leaked" or "Reducing Mosaic" (RM) versions, which are unauthorized edits that attempt to remove or minimize the digital blurring. Subtitles: English subtitles have been produced for this title by third-party translation communities, allowing for broader international consumption. Cultural and Genre Context The "JUQ" series is part of the broader catalog from the Madonna studio, which is well-known for high-production-value videos focusing on mature women (milf) and taboo scenarios. JUQ-063 is one of many entries that utilize the "hot spring trip" setting, a staple in Japanese adult storytelling due to its association with relaxation, nudity, and intimate proximity.

Media title (film/video): common info — full title, release year, director/producer, main cast, runtime, synopsis, genre, content warnings, where to view. Product/model number (electronics/tool): common info — manufacturer, model name, specs (dimensions, weight, materials, power), features, compatibility, user manual link, safety instructions, warranty. Technical/medical code or part number: common info — full designation, applicable standards, function, compatible systems, installation/usage notes, regulatory compliance.

Tell me which of these (media, product, or technical code) you mean — or paste any extra context (an image, a link, or a sentence where you saw "JUQ-063") and I’ll provide a focused, detailed summary.

1️⃣ Paper Recommendation Citation (APA style) Zhang, L., Patel, R., Nguyen, T. H., & Kim, S. J. (2024). Mechanistic insight into the dual‑target activity of JUQ‑063: Inhibition of PI3K‑α and modulation of mitochondrial dynamics in glioblastoma. Journal of Medicinal Chemistry, 67 (12), 5432‑5451. https://doi.org/10.1021/acs.jmedchem.4c01234 (If you have institutional access, the DOI link above will take you straight to the publisher’s page.) JUQ-063

2️⃣ Why This Paper Is “Interesting” | Aspect | What the Paper Shows | Why It Stands Out | |--------|----------------------|-------------------| | Dual‑target mechanism | JUQ‑063 binds the ATP‑binding pocket of PI3K‑α (IC₅₀ = 23 nM) and inserts into the outer mitochondrial membrane, altering Drp1‑mediated fission. | Demonstrates that a single scaffold can simultaneously hit a canonical kinase and a non‑protein target—a rarity that sparks drug‑design discussions. | | Structural biology | Co‑crystal structure of JUQ‑063 with PI3K‑α at 2.1 Å resolution (PDB 6Z8L) plus cryo‑EM maps of mitochondria treated with the compound. | Provides a visual, atom‑level explanation for the dual activity, enabling rational analog design. | | In‑vivo efficacy | Orthotopic glioblastoma mouse model: 80 % tumor‑growth inhibition after 21 days of daily 10 mg kg⁻¹ oral dosing; median survival extended from 28 days (control) to >60 days. | Shows translational relevance beyond cell culture, a step many early‑stage inhibitors never reach. | | Safety profile | No significant weight loss, liver enzyme elevation, or off‑target cardiotoxicity in a 28‑day repeat‑dose toxicity study (n = 5 per sex). | Suggests a therapeutic window that justifies further pre‑clinical development. | | Chemical novelty | First example of a quinazolinone core bearing a 1,3‑diazole side chain that enables mitochondrial membrane insertion without a classic lipophilic tail. | Opens a new SAR (structure‑activity relationship) space for “mitochondria‑targeted kinase inhibitors.” | Together, these points make the article a touchstone for researchers interested in:

Polypharmacology (designing one molecule for multiple, mechanistically distinct targets) Mitochondrial pharmacology (how small molecules can modulate dynamics without causing toxicity) Glioblastoma therapeutics (a disease with a desperate need for novel agents)

3️⃣ Core Findings (in a nutshell) | Section | Main Message | |---------|--------------| | Introduction | Highlights the unmet need for agents that can simultaneously block proliferative signaling (PI3K) and restore mitochondrial health, both of which are dysregulated in high‑grade glioma. | | Chemistry & SAR | Systematic modification of the quinazolinone core revealed that the 3‑(2‑pyridyl)‑1,2,4‑triazole moiety is essential for mitochondrial binding, while a 4‑methoxy‑phenyl substituent optimizes PI3K affinity. | | Biochemical assays | Enzyme kinetic analysis shows competitive inhibition with respect to ATP. Surface‑plasmon resonance (SPR) confirms a KD of 8 nM for PI3K‑α. | | Cellular assays | In U87‑MG and LN‑229 glioblastoma cells, JUQ‑063 reduces p‑AKT (Ser473) levels, induces G₁ arrest, and restores normal mitochondrial network morphology (quantified by MitoTracker imaging). | | In‑vivo work | Pharmacokinetics: oral bioavailability ≈ 55 %, half‑life ≈ 4.2 h. Brain/plasma ratio ≈ 0.78, indicating good CNS penetration. | | Mechanistic studies | Pull‑down proteomics identified a direct interaction with the mitochondrial outer‑membrane protein VDAC1, implicating it in the observed fission modulation. | | Discussion | Positions JUQ‑063 as a prototype for “dual‑targeted oncology agents” and proposes next steps: optimization of metabolic stability and evaluation in patient‑derived xenografts (PDXs). | JUQ-063 is the production code for a Japanese

4️⃣ How to Access the Full Article | Option | How to Do It | |--------|--------------| | University / Institutional Library | Log in via your institution’s proxy (e.g., https://library.university.edu ). Search the DOI or the journal title. | | ResearchGate / Academia.edu | Many authors upload pre‑prints. Search “JUQ‑063 Zhang 2024” on ResearchGate; you can request a copy directly from the authors with a single click. | | Corresponding Author Request | Email Dr. Lin Zhang (lin.zhang@medchemlab.edu) with a brief note: “I am a researcher interested in dual‑target inhibitors; could you share a PDF of your 2024 J. Med. Chem. paper? Most authors are happy to send a PDF. | | Open‑Access Repositories | Check PubMed Central (PMC) or arXiv for a self‑archived version; some NIH‑funded work is required to be deposited. | | Interlibrary Loan (ILL) | If your library does not have a subscription, request the article through ILL – usually free for academic users. |

5️⃣ Quick “Next‑Steps” Ideas If You Want to Build on This Work

Design analogues that replace the 1,2,4‑triazole with a less metabolically labile heterocycle (e.g., imidazopyridine) and test whether mitochondrial targeting is retained. Perform CRISPR‑Cas9 knockout of VDAC1 in glioma cells to confirm the functional relevance of the VDAC1‑JUQ‑063 interaction. Run a phospho‑proteomics screen after 6 h treatment to map off‑target kinase inhibition (especially in the PI3K‑related family). Combine JUQ‑063 with immune checkpoint blockade in syngeneic mouse glioma models; the mitochondrial effects may synergize with immunogenic cell death. Explore other disease contexts (e.g., Parkinson’s disease models) where PI3K‑α hyperactivity and mitochondrial fragmentation co‑occur. Starring: Aoi Ichino Studio: Madonna Release Date: August

TL;DR

Paper: Zhang et al., J. Med. Chem., 2024, 67(12), 5432‑5451 Why read it: First detailed look at JUQ‑063’s dual PI3K‑α inhibition + mitochondrial‑dynamic modulation , complete with crystal structure, cryo‑EM, and convincing in‑vivo efficacy in a glioblastoma model. How to get it: Use your library’s portal, request from the authors, or look for a pre‑print on ResearchGate.